US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Circor

56.00

+0.0000

Volume:- -

Turnover:- -

Market Cap:1.14B

PE:41.00

High:56.00

Open:56.00

Low:56.00

Close:56.00

Loading ...

Overview Company News Filings

Press Release: ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update

GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

Press Release: Abivax Announces Full Year 2024 Financial Results

GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

Space Norway selects Telesat Lightspeed Low Earth Orbit (LEO) connectivity solution

GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors

Press Release: Ekinops FY 2024 results: EBITDA margin of 15.3% and strong generation of operating cash flow

GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

Press Release: ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update

Is KB Financial Group (KB) the Best Asian Stock to Invest in According to Analysts?

CIR Says Shares Tendered At End Of Partial Offer On Own Shares Reach 125.38%

Press Release: Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

CIR SpA Launches Partial Public Share Purchase Offer

CIR S.p.A. Completes Share Offering Successfully

CIR S.p.A. Resumes Italian Public Purchase Offer

OCBC 3QFY2024 net profit up 9% y-o-y, 2% q-o-q to $1.97 billion

Press Release: ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CIR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CIR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CIR\",,,,,undefined,":{"symbol":"CIR","market":"US","secType":"STK","nameCN":"Circor","latestPrice":56,"timestamp":1745265600000,"preClose":56,"halted":0,"volume":0,"delay":0,"floatShares":20070120,"shares":20391768,"eps":1.36571,"marketStatus":"Pre-Mkt","change":0,"latestTime":"04-22 07:17:53 EDT","open":56,"high":56,"low":56,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.36571,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":939787200000,"exchange":"NYSE","adjPreClose":56,"volumeRatio":2.524395050005905,"impliedVol":0.3246,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CIR\",,,,,undefined,":{"symbol":"CIR","floatShares":20070120,"roa":"4.73%","roe":"21.76%","lyrEps":0.952727,"volumeRatio":2.524395050005905,"shares":20391768,"dividePrice":0.15,"high":56,"amplitude":0,"preClose":56,"low":56,"week52Low":56,"pbRate":"7.46","psRate":"1.39","week52High":56,"institutionHeld":0.9759,"latestPrice":56,"eps":1.36571,"divideRate":0.002679,"volume":0,"delay":0,"ttmEps":1.36571,"open":56,"prevYearClose":56,"prevWeekClose":56,"prevMonthClose":56,"prevQuarterClose":56,"fiveDayClose":56,"twentyDayClose":56,"sixtyDayClose":56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CIR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528728844","title":"Press Release: ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2528728844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528728844?lang=en_us&edition=fundamental","pubTime":"2025-04-18 00:00","pubTimestamp":1744905600,"startTime":"0","endTime":"0","summary":"-- Cash position of EUR7.5m  as of December 31, 2024, including:. -- EUR2m received from private placement in March 2024. -- EUR9.8m from an equity financing line  with Vester. -- Cash runway extended until Q2 2026, including EUR9.7m from the private. placement completed in February 2025 and a $10m milestone payment from. partner Tonghua Dongbao expected at the end of Q2 2025. -- BioChaperone Lispro final dosing of Phase 3 studies in China,with top-line data expected in mid-2025 and submission for Chinese. combination of cagrilintide and semaglutide) and M1Pram, covered. \"Our cash horizon is secured until Q2 2026, thanks to the EUR9.7m capital raise in February 2025 and the payment expected in Q2 2025 of the $10m milestone from our Chinese partner\" adds Mathieu-William Gilbert, CFO-COO of Adocia. \"This will enable us to focus on what our shareholders are expecting from us in 2025 -- signing deals, on M1Pram and on BC CagriSema, that will secure Adocia's future in the coming years, and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","CIR","BK4022","R","BK4161"],"gpt_icon":0},{"id":"2525607879","title":"GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2525607879","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525607879?lang=en_us&edition=fundamental","pubTime":"2025-04-08 02:14","pubTimestamp":1744049640,"startTime":"0","endTime":"0","summary":"Operations funded until early June 2025 as a result of disciplined spending controls. Discussions with French agency ANSM regarding the early access program  for LUMEVOQ progressing. Fundraising activities planned to extend runway, focusing on kicking off RECOVER Phase III trial and advancing MHRA marketing application. GenSight Biologics  , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2025, and provided a business update.\"By maintaining disciplined spending controls and prioritizing expenses, we have been able to extend our financial horizon without compromising our core mission,\" commented Jan Eryk Umiastowski, CFO of GenSight Biologics. \"Fundraising activities are planned to extend the cash runway. We are maintaining a forward-looking approach that demonstrates our commitment to responsible financial management while","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gensight-biologics-reports-cash-position-181400257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CIR","BK4161","GSGTF"],"gpt_icon":0},{"id":"2521642937","title":"Press Release: Abivax Announces Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521642937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521642937?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:30","pubTimestamp":1742801400,"startTime":"0","endTime":"0","summary":"--        Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025. -- Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for. moderately to severely active ulcerative colitis  expected in Q2. 2025 with top-line results from the 8-week induction trials expected in. Marc de Garidel, CEO of Abivax, commented: \"2025 is set to be a transformational year for Abivax, marking a pivotal moment in our journey. We are very pleased with our achievements in 2024, demonstrating both strong financial discipline and significant clinical progress. Our cash position secures a projected financial runway into Q4 2025, supporting the full enrollment of ABTECT in Q2 2025 and the anticipated top-line results from the 8-week induction trials in Q3 2025, a major inflection point for Abivax.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CIR","BK4116","CD"],"gpt_icon":0},{"id":"2520150371","title":"GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520150371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520150371?lang=en_us&edition=fundamental","pubTime":"2025-03-20 01:00","pubTimestamp":1742403600,"startTime":"0","endTime":"0","summary":"GenSight Biologics , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2024 are in line with the estimated figures published on February 27, 2025.The definitive consolidated and individual accounts, which were reviewed by the Audit Committee on March 17, 2025, and approved by the Board of Directors on March 18, 2025, confirm the following key financial indicators as previously estimated:. As of December 31, 2024, the Company had not met the scheduled repayment obligations for certain loans, leaving 0.5 million outstanding. The Company initiated discussions with its banking partners to extend the maturity dates of these loans. While no lender—neither the EIB, Heights Capital, nor the banks that granted the PGE—has issued a default notice or formally demanded payment of the overdue amounts as of tod","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gensight-biologics-confirms-definitive-full-170000006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CNSL","GSGTF","CIR","BK4161","BK4115"],"gpt_icon":0},{"id":"2518171238","title":"Space Norway selects Telesat Lightspeed Low Earth Orbit (LEO) connectivity solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2518171238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518171238?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:00","pubTimestamp":1741690800,"startTime":"0","endTime":"0","summary":"OTTAWA, Canada and OSLO, Norway, March  11, 2025  (GLOBE NEWSWIRE) -- Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, and Space Norway, Northern Eur","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040397/0/en/Space-Norway-selects-Telesat-Lightspeed-Low-Earth-Orbit-LEO-connectivity-solution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIR","LEO","BK4161"],"gpt_icon":0},{"id":"2517176605","title":"GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2517176605","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517176605?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:29","pubTimestamp":1741332540,"startTime":"0","endTime":"0","summary":"This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia. \"This round of bridge financing, the third since the November submission of our dossier to ANSM to resume compassionate access  program in France, underscores the unwavering confidence of our long-standing investors in our innovative gene therapy program. Notwithstanding the extended time required to re-start the AAC, we remain steadfast in our mission.\" commented Jan Eryk Umiastowski, CFO of GenSight Biologics. \"The support we have received, particularly the renewed commitment from our key stakeholders Bpifrance, Invus and Sofinnova, demonstrates the market's recognition of our potential. With the anticipated research tax credit and our projected cash runway post-AAC resumption, we are positioned to advance our critical therapeutic research and to progress on providing access to LUMEVOQ for patients.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gensight-biologics-announces-financing-amounting-072900846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4156","CIR","BK4139","GSGTF","BK4211","ISBC"],"gpt_icon":0},{"id":"2517923006","title":"Press Release: Ekinops FY 2024 results: EBITDA margin of 15.3% and strong generation of operating cash flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2517923006","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517923006?lang=en_us&edition=fundamental","pubTime":"2025-03-06 03:29","pubTimestamp":1741202940,"startTime":"0","endTime":"0","summary":"\"Bridge\" strategic plan: accelerating Ekinops' leadership in the fastest-growing market segments. PARIS, March 5, 2025 /PRNewswire/ -- EKINOPS  , a leading supplier of telecommunications solutions for telecom operators and enterprises, reports its FY 2024 financial statements , as approved by the Board of Directors on March 4, 2025. The statutory auditors have finished auditing the consolidated financial statements and the certification report will be issued shortly.corresponds to current operating income restated for  amortization,depreciation and provisions and  income and expenses linked to share-based. In FY 2024, Ekinops' consolidated revenue stood at 117.7 mEUR, down -9% from the previous year . FY 2024 was characterized by dynamic growth of +11% in Access solutions, driven by the significant rebound in business in France and a number of European countries with operators gradually rebuilding their equipment inventories.Penalized by significant base effect and operators' reluctanc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CIR","BK4215","CSR","BK4142","GHG","EBIT"],"gpt_icon":0},{"id":"2514829973","title":"GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514829973","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514829973?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:57","pubTimestamp":1740643020,"startTime":"0","endTime":"0","summary":"Review of LUMEVOQ dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the MHRA. Cash runway extended to early April 2025 thanks to active cash management and the expected collection of Research Tax Credit  in March. Resumption of the Compassionate Access Program  is now expected to occur in April 2025. GenSight Biologics , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year 2024 consolidated financial results1, as reviewed by the Audit Committee and approved by the Board of Directors on February 26, 2025. The Board of Directors will approve the final accounts on March 18, 2025, and the final certification by the auditors will take place after completion of the required procedures to file the universal registration document w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gensight-biologics-reports-estimated-full-075700052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNSL","LU0149725797.USD","CMC","BK4115","LU0882574139.USD","IE00B1BXHZ80.USD","CIR","IE00BZ1G4Q59.USD","GSGTF","BK4161","LU0267386448.USD","BK4006","BK4139","IE00BHPRN162.USD","LU0971096721.USD","LU0170899867.USD","LU1363072403.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2514017267","title":"Press Release: ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514017267","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514017267?lang=en_us&edition=fundamental","pubTime":"2025-02-26 02:03","pubTimestamp":1740506580,"startTime":"0","endTime":"0","summary":"Cash position of EUR7.5 million as of December 31, 2024. BioChaperone Lispro final dosing of Phase 3 triggered a $10 million. revenue recognition, and top-line data are expected in mid-2025. Ongoing partnership discussions on M1Pram with Sanofi and business. priority to partner the stable combination of cagrilintide and. Adocia , a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity , reports financial results for the fourth quarter of 2024 and provides a business update.\"I am pleased that we have extended our cash runway to the end of 2025, with the upcoming $10 million payment of the BioChaperone Lispro milestone. We have maintained the rigorous management of our operational expenses improving our financial visibility while we direct most of our resources to advance AdoShell Islets to the clinic, based on the promising preclinical results gathered this year\" adds Mathieu-William","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4161","BK4232","R","CIR"],"gpt_icon":0},{"id":"2507699536","title":"Is KB Financial Group (KB) the Best Asian Stock to Invest in According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507699536","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507699536?lang=en_us&edition=fundamental","pubTime":"2025-01-30 06:03","pubTimestamp":1738188189,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Asian Stocks to Invest in According to Analysts.In this article, we are going to take a look at where KB Financial Group Inc.  stands against other best Asian stocks to invest in according to analysts.Herro pointed out that the growth rates of international companies are not solely dependent on their home markets but are influenced by their global operations. For instance, many Asian companies, particularly in sectors such as technology, manufacturing, and consumer goods, have a significant presence in global markets. This global diversification can provide robust growth opportunities, even in the face of local economic challenges. He also highlighted the importance of considering the fundamentals of individual companies rather than just the macroeconomic conditions of their home countri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kb-financial-group-kb-best-220309890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KB","CIR","BK4207","BK4161","ROE"],"gpt_icon":0},{"id":"2491800655","title":"CIR Says Shares Tendered At End Of Partial Offer On Own Shares Reach 125.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491800655","media":"T-Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491800655?lang=en_us&edition=fundamental","pubTime":"2024-12-16 14:32","pubTimestamp":1734330724,"startTime":"0","endTime":"0","summary":"CIR SpA - Compagnie Industriali Riunite :Said On Friday Shares Tendered At End Of Voluntary Partial Public Tender Offer On Own Shares Equals Around 125.38% Of Shares Subject To Offer.Shares Tendered To Be Allocated On Pro-Rata Method, Provisional Allocation Coefficient Is 79.76%. Further Company Coverage: Ciri.Mi. . .","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CIR"],"gpt_icon":0},{"id":"2490471518","title":"Press Release: Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2490471518","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490471518?lang=en_us&edition=fundamental","pubTime":"2024-12-09 14:30","pubTimestamp":1733725800,"startTime":"0","endTime":"0","summary":"Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook. Following the non-adoption of certain financial delegations at the. Redemption of the ORANE held by IRIS due, rendering redemption. of the IPF Partners bonds also due in the absence of a new General. Meeting authorizing the issue of new shares to redeem the ORANE. Without the renewal of the authorization by the General Meeting. and subject to an agreement with its creditors, the Company may. not be able to meet the redemption requests of IRIS and IPF. Suspension by the Company until further notice of the drawdown of new. ORANE tranches under the equity-linked financing facility put in place. adopt new financial delegations to maintain the cash runway to end-2025. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and ra","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CIR"],"gpt_icon":0},{"id":"2485266113","title":"CIR SpA Launches Partial Public Share Purchase Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485266113","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485266113?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:17","pubTimestamp":1732285067,"startTime":"0","endTime":"0","summary":"CIR SpA – Compagnie Industriali Riunite (IT:CIR) has released an update. CIR SpA has announced a voluntary partial public purchase offer for a maxi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cir-spa-launches-partial-public-share-purchase-offer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cir-spa-launches-partial-public-share-purchase-offer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CIR","BK4161"],"gpt_icon":0},{"id":"2483855779","title":"CIR S.p.A. Completes Share Offering Successfully","url":"https://stock-news.laohu8.com/highlight/detail?id=2483855779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483855779?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:50","pubTimestamp":1731523829,"startTime":"0","endTime":"0","summary":"CIR SpA – Compagnie Industriali Riunite (IT:CIR) has released an update. CIR S.p.A. successfully concluded the subscription period for its option a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cir-s-p-a-completes-share-offering-successfully?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cir-s-p-a-completes-share-offering-successfully?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CIR","BK4161"],"gpt_icon":0},{"id":"2483832089","title":"CIR S.p.A. Resumes Italian Public Purchase Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483832089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483832089?lang=en_us&edition=fundamental","pubTime":"2024-11-14 01:20","pubTimestamp":1731518412,"startTime":"0","endTime":"0","summary":"CIR SpA – Compagnie Industriali Riunite (IT:CIR) has released an update. CIR S.p.A. has announced the resumption of investigatory terms by Consob f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cir-s-p-a-resumes-italian-public-purchase-offer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cir-s-p-a-resumes-italian-public-purchase-offer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","CIR"],"gpt_icon":0},{"id":"2481120961","title":"OCBC 3QFY2024 net profit up 9% y-o-y, 2% q-o-q to $1.97 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2481120961","media":"Jovi Ho","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481120961?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:17","pubTimestamp":1730992679,"startTime":"0","endTime":"0","summary":"The earnings beat consensus estimates of around $1.9 billion. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/results/ocbc-3qfy2024-net-profit-9-y-o-y-2-q-o-q-197-billion?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["SG9999000459.SGD","IE0031814969.USD","NIM","SG9999001903.USD","O39.SI","LU1048588211.SGD","CIR","LU0264606111.USD","IE00B067MR52.USD","LU1206713676.USD","ROE","LU0072462343.USD","SG9999003826.SGD","SGXZ27511609.SGD","LU0261945553.USD","LU0181495838.USD","SG9999013486.USD","IE00B0169L03.USD","SG9999004360.SGD","SG9999002604.SGD","SGXZ24219693.SGD","IE0032834883.USD","LU0955669360.SGD","LU1497734951.SGD","LU0210637038.USD","LU1497733631.SGD","LCR","BK4161","LU1130305938.SGD","LU1981816686.USD","LU0737861269.HKD","BK6523","BK6112","LU1497733557.USD","SG9999014302.SGD","SG9999002406.SGD","IE0008368411.USD","SG9999000327.SGD","BK6516","SG9999013460.SGD","LU0955648018.USD","LU0572940350.SGD","IE00B031HW06.USD","LU0532188223.SGD","LU1634259557.SGD","SG9999000475.SGD","SG9999001689.USD","SG9999016042.SGD","SG9999002679.SGD","SG9999001127.SGD"],"gpt_icon":1},{"id":"2479516734","title":"Press Release: ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2479516734","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479516734?lang=en_us&edition=fundamental","pubTime":"2024-10-31 01:00","pubTimestamp":1730307600,"startTime":"0","endTime":"0","summary":"-- Cash position of EUR9.3 million as of September 30, 2024. -- Completion of the Phase 3 study on BioChaperone Lispro expected in. December 2024, associated with a $10 million payment by Tonghua Dongbao. -- Development of a stable combination of cagrilintide and semaglutide. -- Ongoing partnership discussions on M1Pram with Sanofi. Adocia , a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the third quarter of 2024 and provides a business update.\"We are maintaining our cash runway until the third quarter of 2025 thanks to rigorous management, focused on our strategic projects. The PACEO, established in March 2024, is a controlled financing solution pending revenues from BioChaperone Lispro and the conclusion of other partnerships that could generate significant income\", adds Mathieu-William Gilbert, COO-CFO of Adocia.The Company's cash position ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","IE00B7SZL793.SGD","COO","IE00B19Z4B17.USD","CFO","BK4232","CIR","LU2211815571.USD","GB00BDT5M118.USD","LU1992135472.HKD","LU2272731782.SGD","BK4006","BK4198","IE0031619046.USD","LU1992135399.USD","BK4588","LU2272731600.USD","R","IE00B66KJ199.SGD","BK4161","CRS"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CIR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-10-18","symbol":"CIR","reason":null,"defaultRemindTime":1697635800000,"announcedDate":"2023-10-17","type":"delisting","dateTimestamp":1697601600000},{"market":"US","date":"2023-08-10","symbol":"CIR","fiscalQuarterEnding":"2023/06","expectedEps":0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1691640000000,"reportTimeType":"pre","actualEps":0.57},{"market":"US","date":"2023-05-11","symbol":"CIR","fiscalQuarterEnding":"2023/03","expectedEps":0.12,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1683777600000,"reportTimeType":"pre","actualEps":0.53},{"market":"US","date":"2023-03-15","symbol":"CIR","fiscalQuarterEnding":"2022/12","expectedEps":0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1678852800000,"reportTimeType":"pre","actualEps":0.77},{"market":"US","date":"2022-09-30","symbol":"CIR","fiscalQuarterEnding":"2022/06","expectedEps":0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1664510400000,"reportTimeType":"pre","actualEps":0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CIR\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-21","recordDate":"2017-02-23","paymentDate":"2017-03-09","value":0.0375,"currency":"USD"},{"executeDate":"2017-05-23","recordDate":"2017-05-25","paymentDate":"2017-06-08","value":0.0375,"currency":"USD"},{"executeDate":"2017-08-14","recordDate":"2017-08-16","paymentDate":"2017-08-30","value":0.0375,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":"2017-11-28","paymentDate":"2017-12-12","value":0.0375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CIR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1686024000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CIR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CIR","date":"2023-10-18","current":40.884287,"percent":1,"low":-55.722444,"twenty":-17.883207,"median":-5.126402,"eighty":-2.657635,"high":40.884287,"avg":-7.464077,"sd":16.655433,"marketCap":1141939008},"quantilePoints":[{"date":"2020-04-24","current":-1.587032,"twenty":-21.765745,"median":14.31276,"eighty":75.556178,"marketCap":218632661},{"date":"2020-05-01","current":-1.826392,"twenty":-21.765745,"median":14.21236,"eighty":75.556178,"marketCap":251607423},{"date":"2020-05-08","current":-1.736451,"twenty":-21.765745,"median":14.162835,"eighty":75.556178,"marketCap":239216906},{"date":"2020-05-15","current":-1.549314,"twenty":-21.765745,"median":14.06437,"eighty":75.556178,"marketCap":213436638},{"date":"2020-05-22","current":-1.927939,"twenty":-21.765745,"median":13.985197,"eighty":75.556178,"marketCap":265596716},{"date":"2020-05-29","current":-1.543117,"twenty":-21.765745,"median":13.963686,"eighty":75.556178,"marketCap":321354040},{"date":"2020-06-05","current":-2.213353,"twenty":-21.765745,"median":13.886732,"eighty":75.556178,"marketCap":460930843},{"date":"2020-06-12","current":-2.036746,"twenty":-21.765745,"median":13.840104,"eighty":75.556178,"marketCap":424152320},{"date":"2020-06-19","current":-2.242148,"twenty":-21.765745,"median":13.77433,"eighty":75.556178,"marketCap":466927342},{"date":"2020-06-26","current":-2.212394,"twenty":-21.765745,"median":13.703879,"eighty":75.556178,"marketCap":460730960},{"date":"2020-07-02","current":-2.398599,"twenty":-21.765745,"median":13.666867,"eighty":75.556178,"marketCap":499508316},{"date":"2020-07-10","current":-2.276702,"twenty":-21.765745,"median":13.622664,"eighty":75.556178,"marketCap":474123140},{"date":"2020-07-17","current":-2.66735,"twenty":-21.765745,"median":13.566299,"eighty":75.556178,"marketCap":555475635},{"date":"2020-07-24","current":-2.680788,"twenty":-21.765745,"median":13.516159,"eighty":75.556178,"marketCap":558274001},{"date":"2020-07-31","current":-2.516658,"twenty":-21.765745,"median":13.407218,"eighty":75.556178,"marketCap":524093960},{"date":"2020-08-07","current":-2.885821,"twenty":-21.765745,"median":13.336855,"eighty":75.556178,"marketCap":645910141},{"date":"2020-08-14","current":-2.753591,"twenty":-21.765745,"median":13.254153,"eighty":75.556178,"marketCap":616314258},{"date":"2020-08-21","current":-2.489132,"twenty":-21.765745,"median":13.11146,"eighty":75.556178,"marketCap":557122493},{"date":"2020-08-28","current":-2.708025,"twenty":-21.765745,"median":12.794797,"eighty":75.556178,"marketCap":606115677},{"date":"2020-09-04","current":-2.597239,"twenty":-21.765745,"median":12.533255,"eighty":75.556178,"marketCap":581319127},{"date":"2020-09-11","current":-2.411402,"twenty":-21.765745,"median":12.307413,"eighty":75.556178,"marketCap":539724913},{"date":"2020-09-18","current":-2.479304,"twenty":-21.765745,"median":11.995926,"eighty":75.556178,"marketCap":554922799},{"date":"2020-09-25","current":-2.381025,"twenty":-21.765745,"median":11.796679,"eighty":75.556178,"marketCap":532925859},{"date":"2020-10-02","current":-2.512361,"twenty":-21.765745,"median":11.620487,"eighty":75.556178,"marketCap":562321770},{"date":"2020-10-09","current":-2.648165,"twenty":-21.765745,"median":11.483814,"eighty":75.556178,"marketCap":592717541},{"date":"2020-10-16","current":-2.648165,"twenty":-21.765745,"median":11.238461,"eighty":75.556178,"marketCap":592717541},{"date":"2020-10-23","current":-2.671394,"twenty":-21.765745,"median":11.057329,"eighty":75.556178,"marketCap":597916818},{"date":"2020-10-30","current":-2.492706,"twenty":-21.765745,"median":-1.404942,"eighty":75.556178,"marketCap":557922382},{"date":"2020-11-06","current":-3.352464,"twenty":-21.765745,"median":-1.509696,"eighty":75.556178,"marketCap":569945764},{"date":"2020-11-13","current":-3.933558,"twenty":-21.765745,"median":-1.551249,"eighty":75.556178,"marketCap":668736363},{"date":"2020-11-20","current":-4.193521,"twenty":-21.765745,"median":-1.592837,"eighty":75.556178,"marketCap":712932158},{"date":"2020-11-27","current":-4.259394,"twenty":-21.765745,"median":-1.637244,"eighty":75.556178,"marketCap":724131092},{"date":"2020-12-04","current":-4.47701,"twenty":-21.765745,"median":-1.671896,"eighty":75.556178,"marketCap":761127571},{"date":"2020-12-11","current":-4.281744,"twenty":-21.765745,"median":-1.700298,"eighty":75.556178,"marketCap":727930730},{"date":"2020-12-18","current":-4.367614,"twenty":-21.765745,"median":-1.741265,"eighty":75.556178,"marketCap":742529341},{"date":"2020-12-24","current":-4.346441,"twenty":-21.765745,"median":-1.830018,"eighty":75.556178,"marketCap":738929684},{"date":"2020-12-31","current":-4.52171,"twenty":-21.765745,"median":-1.882694,"eighty":75.556178,"marketCap":768726848},{"date":"2021-01-08","current":-4.480539,"twenty":-21.765745,"median":-1.943643,"eighty":75.556178,"marketCap":761727514},{"date":"2021-01-15","current":-4.493479,"twenty":-21.765745,"median":-2.075138,"eighty":75.556178,"marketCap":763927305},{"date":"2021-01-22","current":-4.261747,"twenty":-21.765745,"median":-2.154088,"eighty":75.556178,"marketCap":724531054},{"date":"2021-01-29","current":-3.760642,"twenty":-21.765745,"median":-2.209515,"eighty":75.556178,"marketCap":639339161},{"date":"2021-02-05","current":-4.004136,"twenty":-21.765745,"median":-2.267622,"eighty":75.556178,"marketCap":680735221},{"date":"2021-02-12","current":-3.934735,"twenty":-21.765745,"median":-2.313976,"eighty":75.556178,"marketCap":668936344},{"date":"2021-02-19","current":-4.099417,"twenty":-21.765745,"median":-2.341296,"eighty":75.556178,"marketCap":696933680},{"date":"2021-02-26","current":-4.188816,"twenty":-21.765745,"median":-2.372286,"eighty":75.556178,"marketCap":712132234},{"date":"2021-03-05","current":-3.209522,"twenty":-21.782316,"median":-2.412296,"eighty":75.562894,"marketCap":701646481},{"date":"2021-03-12","current":-3.735598,"twenty":-21.782316,"median":-2.443566,"eighty":75.562894,"marketCap":816654099},{"date":"2021-03-19","current":-3.248051,"twenty":-21.782316,"median":-2.465902,"eighty":75.562894,"marketCap":710069492},{"date":"2021-03-26","current":-3.117134,"twenty":-21.765745,"median":-2.484218,"eighty":75.556178,"marketCap":681449036},{"date":"2021-04-01","current":-3.260959,"twenty":-21.765745,"median":-2.513254,"eighty":75.556178,"marketCap":712891227},{"date":"2021-04-09","current":-3.165075,"twenty":-21.782316,"median":-2.542739,"eighty":75.562894,"marketCap":691929766},{"date":"2021-04-16","current":-3.175761,"twenty":-21.782316,"median":-2.586517,"eighty":75.562894,"marketCap":694265890},{"date":"2021-04-23","current":-3.117634,"twenty":-21.782316,"median":-2.607066,"eighty":75.562894,"marketCap":681558525},{"date":"2021-04-30","current":-3.171148,"twenty":-21.782316,"median":-2.635676,"eighty":75.562894,"marketCap":693257369},{"date":"2021-05-07","current":-3.446098,"twenty":-21.782316,"median":-2.663353,"eighty":75.562894,"marketCap":753365224},{"date":"2021-05-14","current":-4.955379,"twenty":-21.782316,"median":-2.671394,"eighty":75.562894,"marketCap":750551656},{"date":"2021-05-21","current":-4.950032,"twenty":-21.782316,"median":-2.685689,"eighty":75.562894,"marketCap":749741781},{"date":"2021-05-28","current":-5.030238,"twenty":-21.782316,"median":-2.701771,"eighty":75.562894,"marketCap":761889906},{"date":"2021-06-04","current":-5.154557,"twenty":-21.782316,"median":-2.713422,"eighty":75.562894,"marketCap":780719500},{"date":"2021-06-11","current":-4.970084,"twenty":-21.782316,"median":-2.750017,"eighty":75.562894,"marketCap":752778812},{"date":"2021-06-18","current":-4.355173,"twenty":-21.782316,"median":-2.885821,"eighty":75.562894,"marketCap":659643187},{"date":"2021-06-25","current":-4.396612,"twenty":-21.782316,"median":-3.011109,"eighty":75.562894,"marketCap":665919718},{"date":"2021-07-02","current":-4.286998,"twenty":-21.782316,"median":-3.055363,"eighty":75.562894,"marketCap":649317281},{"date":"2021-07-09","current":-4.308386,"twenty":-21.765745,"median":-3.105179,"eighty":75.556178,"marketCap":652556781},{"date":"2021-07-16","current":-3.903347,"twenty":-21.765745,"median":-3.134905,"eighty":75.556178,"marketCap":591208750},{"date":"2021-07-23","current":-3.99692,"twenty":-21.765745,"median":-3.163037,"eighty":75.556178,"marketCap":605381562},{"date":"2021-07-30","current":-4.122576,"twenty":-21.765745,"median":-3.18794,"eighty":75.556178,"marketCap":624413625},{"date":"2021-08-06","current":-4.095841,"twenty":-21.765745,"median":-3.228229,"eighty":75.556178,"marketCap":620364250},{"date":"2021-08-13","current":-4.75847,"twenty":-21.765745,"median":-3.310303,"eighty":75.556178,"marketCap":647884768},{"date":"2021-08-20","current":-4.877469,"twenty":-21.765745,"median":-3.40975,"eighty":75.556178,"marketCap":664086951},{"date":"2021-08-27","current":-5.360902,"twenty":-21.765745,"median":-3.498154,"eighty":75.556178,"marketCap":729908317},{"date":"2021-09-03","current":-4.910194,"twenty":-21.765745,"median":-3.70637,"eighty":75.556178,"marketCap":668542551},{"date":"2021-09-10","current":-4.849207,"twenty":-21.765745,"median":-3.830043,"eighty":75.556178,"marketCap":660238932},{"date":"2021-09-17","current":-4.761445,"twenty":-21.765745,"median":-3.88343,"eighty":75.556178,"marketCap":648289823},{"date":"2021-09-24","current":-4.969693,"twenty":-21.765745,"median":-3.917678,"eighty":75.556178,"marketCap":676643642},{"date":"2021-10-01","current":-5.073818,"twenty":-21.765745,"median":-3.945497,"eighty":75.556178,"marketCap":690820552},{"date":"2021-10-08","current":-4.992006,"twenty":-21.765745,"median":-3.995743,"eighty":75.556178,"marketCap":679681551},{"date":"2021-10-15","current":-4.804582,"twenty":-21.765745,"median":-4.011062,"eighty":75.556178,"marketCap":654163114},{"date":"2021-10-22","current":-4.810532,"twenty":-21.765745,"median":-4.043707,"eighty":75.556178,"marketCap":654973223},{"date":"2021-10-29","current":-4.245287,"twenty":-21.749175,"median":-4.074632,"eighty":75.549463,"marketCap":578012857},{"date":"2021-11-05","current":-5.155629,"twenty":-21.749175,"median":-4.091831,"eighty":75.549463,"marketCap":701959552},{"date":"2021-11-12","current":-8.203252,"twenty":-21.749175,"median":-4.108827,"eighty":75.472205,"marketCap":658384837},{"date":"2021-11-19","current":-8.352173,"twenty":-21.749175,"median":-4.138617,"eighty":74.804008,"marketCap":670337054},{"date":"2021-11-26","current":-7.536896,"twenty":-21.749175,"median":-4.160585,"eighty":73.737221,"marketCap":604903730},{"date":"2021-12-03","current":-6.789769,"twenty":-21.749175,"median":-4.198226,"eighty":72.862999,"marketCap":544940065},{"date":"2021-12-10","current":-6.928593,"twenty":-21.749175,"median":-4.245287,"eighty":71.622064,"marketCap":556081962},{"date":"2021-12-17","current":-6.433874,"twenty":-21.749175,"median":-4.27363,"eighty":70.442078,"marketCap":516376292},{"date":"2021-12-23","current":-6.903352,"twenty":-21.749175,"median":-4.286998,"eighty":69.598708,"marketCap":554056163},{"date":"2021-12-31","current":-6.860443,"twenty":-21.749175,"median":-4.308386,"eighty":68.750071,"marketCap":550612304},{"date":"2022-01-07","current":-6.484356,"twenty":-21.732604,"median":-4.350138,"eighty":68.471556,"marketCap":520427891},{"date":"2022-01-14","current":-6.204183,"twenty":-21.732604,"median":-4.369967,"eighty":67.672828,"marketCap":497941517},{"date":"2022-01-21","current":-6.764528,"twenty":-21.732604,"median":-4.396228,"eighty":66.407747,"marketCap":542914266},{"date":"2022-01-28","current":-6.653469,"twenty":-21.732604,"median":-4.42241,"eighty":65.338483,"marketCap":534000748},{"date":"2022-02-04","current":-6.595415,"twenty":-21.732604,"median":-4.455837,"eighty":63.877585,"marketCap":529341409},{"date":"2022-02-11","current":-6.888208,"twenty":-21.732604,"median":-4.497008,"eighty":61.885919,"marketCap":552840683},{"date":"2022-02-18","current":-7.092658,"twenty":-21.732604,"median":-4.531373,"eighty":60.139025,"marketCap":569249659},{"date":"2022-02-25","current":-6.767052,"twenty":-21.732604,"median":-4.572573,"eighty":52.391885,"marketCap":543116845},{"date":"2022-03-04","current":-6.130985,"twenty":-21.732604,"median":-4.612491,"eighty":50.015143,"marketCap":492066698},{"date":"2022-03-11","current":-6.098172,"twenty":-21.732604,"median":-4.645421,"eighty":48.01199,"marketCap":489433159},{"date":"2022-03-18","current":-7.302157,"twenty":-21.732604,"median":-4.704177,"eighty":41.510523,"marketCap":586063795},{"date":"2022-03-25","current":-7.004316,"twenty":-21.732604,"median":-4.749545,"eighty":40.038591,"marketCap":562159361},{"date":"2022-04-01","current":-6.767052,"twenty":-21.732604,"median":-4.75767,"eighty":39.610207,"marketCap":543116845},{"date":"2022-04-08","current":-6.072931,"twenty":-21.732604,"median":-4.790451,"eighty":38.787707,"marketCap":487407359},{"date":"2022-04-14","current":-6.027497,"twenty":-21.732604,"median":-4.817226,"eighty":38.102291,"marketCap":483760920},{"date":"2022-04-22","current":-5.92401,"twenty":-21.732604,"median":-4.8559,"eighty":37.730452,"marketCap":475455142},{"date":"2022-04-29","current":-4.959813,"twenty":-21.732604,"median":-4.889369,"eighty":6.284086,"marketCap":398069601},{"date":"2022-05-06","current":-4.54334,"twenty":-21.732604,"median":-4.898021,"eighty":-1.45455,"marketCap":364643910},{"date":"2022-05-13","current":-4.856325,"twenty":-21.732604,"median":-4.901759,"eighty":-1.546915,"marketCap":389763823},{"date":"2022-05-20","current":-4.740218,"twenty":-21.732604,"median":-4.909762,"eighty":-1.580359,"marketCap":380445146},{"date":"2022-05-27","current":-4.901759,"twenty":-21.732604,"median":-4.910194,"eighty":-1.613144,"marketCap":393410262},{"date":"2022-06-03","current":-4.906807,"twenty":-21.732604,"median":-4.9154,"eighty":-1.660435,"marketCap":393815422},{"date":"2022-06-10","current":-4.66702,"twenty":-21.732604,"median":-4.935693,"eighty":-1.680975,"marketCap":374570327},{"date":"2022-06-17","current":-3.952706,"twenty":-21.732604,"median":-4.935693,"eighty":-1.726296,"marketCap":317240201},{"date":"2022-06-24","current":-3.924941,"twenty":-21.749175,"median":-4.939338,"eighty":-1.763585,"marketCap":315011822},{"date":"2022-07-01","current":-4.073861,"twenty":-21.749175,"median":-4.939338,"eighty":-1.85342,"marketCap":326964039},{"date":"2022-07-08","current":-3.909796,"twenty":-21.749175,"median":-4.939338,"eighty":-1.925725,"marketCap":313796342},{"date":"2022-07-15","current":-3.723015,"twenty":-21.749175,"median":-4.939338,"eighty":-2.025612,"marketCap":298805426},{"date":"2022-07-22","current":-3.871935,"twenty":-21.749175,"median":-4.939338,"eighty":-2.138389,"marketCap":310757643},{"date":"2022-07-29","current":-5.748495,"twenty":-21.749175,"median":-4.957289,"eighty":-2.202795,"marketCap":354325760},{"date":"2022-08-05","current":-5.807928,"twenty":-21.749175,"median":-4.971958,"eighty":-2.262861,"marketCap":357989094},{"date":"2022-08-12","current":-5.635168,"twenty":-21.749175,"median":-4.992006,"eighty":-2.302426,"marketCap":401917099},{"date":"2022-08-19","current":-5.452468,"twenty":-21.749175,"median":-5.038118,"eighty":-2.341737,"marketCap":388886352},{"date":"2022-08-26","current":-4.921494,"twenty":-21.749175,"median":-5.046279,"eighty":-2.373358,"marketCap":351015744},{"date":"2022-09-02","current":-4.470453,"twenty":-21.749175,"median":-5.046279,"eighty":-2.411938,"marketCap":318846087},{"date":"2022-09-09","current":-4.987419,"twenty":-21.749175,"median":-5.046279,"eighty":-2.438206,"marketCap":355717693},{"date":"2022-09-16","current":-4.801854,"twenty":-21.749175,"median":-5.048155,"eighty":-2.453145,"marketCap":342482633},{"date":"2022-09-23","current":-4.1224,"twenty":-21.749175,"median":-5.048155,"eighty":-2.477874,"marketCap":294021951},{"date":"2022-09-30","current":-6.91228,"twenty":-21.749175,"median":-5.050018,"eighty":-2.513433,"marketCap":335791641},{"date":"2022-10-07","current":-7.415296,"twenty":-21.749175,"median":-5.069004,"eighty":-2.533447,"marketCap":360227661},{"date":"2022-10-14","current":-6.895513,"twenty":-21.749175,"median":-5.089056,"eighty":-2.585802,"marketCap":334977107},{"date":"2022-10-21","current":-7.58716,"twenty":-21.749175,"median":-5.128855,"eighty":-2.605279,"marketCap":368576635},{"date":"2022-10-28","current":-8.484205,"twenty":-21.749175,"median":-5.165251,"eighty":-2.634239,"marketCap":412154204},{"date":"2022-11-04","current":-8.647685,"twenty":-21.749175,"median":-5.1984,"eighty":-2.657635,"marketCap":420095910},{"date":"2022-11-11","current":-9.087825,"twenty":-21.749175,"median":-5.241904,"eighty":-2.669965,"marketCap":441477428},{"date":"2022-11-18","current":-35.410853,"twenty":-22.325839,"median":-5.283659,"eighty":-2.684975,"marketCap":512749153},{"date":"2022-11-25","current":-35.495232,"twenty":-22.735138,"median":-5.310328,"eighty":-2.694801,"marketCap":513970954},{"date":"2022-12-02","current":-38.378164,"twenty":-23.13335,"median":-5.353633,"eighty":-2.711263,"marketCap":555715821},{"date":"2022-12-09","current":-36.437458,"twenty":-23.488325,"median":-5.39689,"eighty":-2.746129,"marketCap":527614398},{"date":"2022-12-16","current":-33.84985,"twenty":-23.757556,"median":-5.438194,"eighty":-2.841817,"marketCap":490145834},{"date":"2022-12-23","current":-33.413895,"twenty":-24.207589,"median":-5.453561,"eighty":-3.004627,"marketCap":483833196},{"date":"2022-12-30","current":-33.695156,"twenty":-24.761746,"median":-5.503759,"eighty":-3.051388,"marketCap":487905866},{"date":"2023-01-06","current":-34.07486,"twenty":-25.259494,"median":-5.550832,"eighty":-3.093646,"marketCap":493403970},{"date":"2023-01-13","current":-37.08436,"twenty":-25.519347,"median":-5.580094,"eighty":-3.1252,"marketCap":536981539},{"date":"2023-01-20","current":-34.904582,"twenty":-26.234891,"median":-5.590272,"eighty":-3.1533,"marketCap":505418347},{"date":"2023-01-27","current":-36.578089,"twenty":-27.010404,"median":-5.616989,"eighty":-3.180743,"marketCap":529650733},{"date":"2023-02-03","current":-38.884436,"twenty":-27.327806,"median":-5.635168,"eighty":-3.209522,"marketCap":563046627},{"date":"2023-02-10","current":-37.745326,"twenty":-27.452844,"median":-5.646362,"eighty":-3.277932,"marketCap":546552314},{"date":"2023-02-17","current":-37.618758,"twenty":-27.935054,"median":-5.675513,"eighty":-3.353285,"marketCap":544719612},{"date":"2023-02-24","current":-39.798536,"twenty":-28.339584,"median":-5.679329,"eighty":-3.443691,"marketCap":576282805},{"date":"2023-03-03","current":-41.472044,"twenty":-28.846118,"median":-5.70223,"eighty":-3.558471,"marketCap":600515191},{"date":"2023-03-10","current":-36.690594,"twenty":-29.560532,"median":-5.735308,"eighty":-3.662664,"marketCap":531279801},{"date":"2023-03-17","current":30.913481,"twenty":-29.882542,"median":-5.743647,"eighty":-3.704666,"marketCap":599350572},{"date":"2023-03-24","current":31.354652,"twenty":-29.882542,"median":-5.743647,"eighty":-3.704666,"marketCap":607903996},{"date":"2023-03-31","current":32.688669,"twenty":-29.858579,"median":-5.742769,"eighty":-3.675959,"marketCap":633767918},{"date":"2023-04-06","current":31.564734,"twenty":-29.858579,"median":-5.742769,"eighty":-3.675959,"marketCap":611977054},{"date":"2023-04-14","current":30.892473,"twenty":-29.882542,"median":-5.743647,"eighty":-3.704666,"marketCap":598943267},{"date":"2023-04-21","current":29.348375,"twenty":-29.882542,"median":-5.743647,"eighty":-3.704666,"marketCap":569006286},{"date":"2023-04-28","current":29.547952,"twenty":-29.882542,"median":-5.743647,"eighty":-3.704666,"marketCap":572875692},{"date":"2023-05-05","current":27.594195,"twenty":-29.126247,"median":-5.707319,"eighty":-3.634506,"marketCap":534996247},{"date":"2023-05-12","current":14.868043,"twenty":-28.599209,"median":-5.694596,"eighty":-3.483785,"marketCap":601590755},{"date":"2023-05-19","current":15.077903,"twenty":-28.145504,"median":-5.678693,"eighty":-3.446098,"marketCap":610082114},{"date":"2023-05-26","current":14.715066,"twenty":-27.685384,"median":-5.666433,"eighty":-3.352464,"marketCap":595400994},{"date":"2023-06-02","current":14.715066,"twenty":-27.441245,"median":-5.645034,"eighty":-3.289247,"marketCap":595400994},{"date":"2023-06-09","current":24.053644,"twenty":-27.318369,"median":-5.635168,"eighty":-3.210105,"marketCap":973258563},{"date":"2023-06-16","current":24.083882,"twenty":-26.857952,"median":-5.618262,"eighty":-3.187977,"marketCap":974482019},{"date":"2023-06-21","current":24.124198,"twenty":-26.612705,"median":-5.611874,"eighty":-3.184803,"marketCap":976113292},{"date":"2023-06-30","current":27.112635,"twenty":-25.411665,"median":-5.588363,"eighty":-3.162629,"marketCap":1097031442},{"date":"2023-07-07","current":28.286844,"twenty":-25.265089,"median":-5.57246,"eighty":-3.144207,"marketCap":1144542283},{"date":"2023-07-14","current":28.271725,"twenty":-24.826373,"median":-5.555921,"eighty":-3.13385,"marketCap":1143930555},{"date":"2023-07-19","current":28.222505,"twenty":-24.350791,"median":-5.531748,"eighty":-3.118557,"marketCap":1141939008},{"date":"2023-07-26","current":28.086432,"twenty":-23.924803,"median":-5.503759,"eighty":-3.117234,"marketCap":1136433230},{"date":"2023-08-04","current":28.121711,"twenty":-23.554787,"median":-5.453015,"eighty":-3.084419,"marketCap":1137860654},{"date":"2023-08-11","current":40.752873,"twenty":-23.335684,"median":-5.437898,"eighty":-3.038303,"marketCap":1138268489},{"date":"2023-08-18","current":40.643361,"twenty":-22.909131,"median":-5.387348,"eighty":-2.90993,"marketCap":1135209724},{"date":"2023-08-25","current":40.599557,"twenty":-22.43852,"median":-5.352284,"eighty":-2.766262,"marketCap":1133986218},{"date":"2023-09-01","current":40.657963,"twenty":-21.782316,"median":-5.302147,"eighty":-2.720775,"marketCap":1135617559},{"date":"2023-09-08","current":40.577654,"twenty":-21.482385,"median":-5.282863,"eighty":-2.707311,"marketCap":1133374465},{"date":"2023-09-15","current":40.701767,"twenty":-21.011774,"median":-5.241904,"eighty":-2.691346,"marketCap":1136841066},{"date":"2023-09-22","current":40.665264,"twenty":-18.574466,"median":-5.200954,"eighty":-2.68328,"marketCap":1135821477},{"date":"2023-09-29","current":40.716369,"twenty":-18.4029,"median":-5.170598,"eighty":-2.669965,"marketCap":1137248901},{"date":"2023-10-06","current":40.431639,"twenty":-18.206105,"median":-5.143937,"eighty":-2.66735,"marketCap":1129296111},{"date":"2023-10-18","current":40.884287,"twenty":-17.883207,"median":-5.126402,"eighty":-2.657635,"marketCap":1141939008}],"updateTime":1745289845194}}}